Biotech Startup Checklist
BIOPHARMAWIRE | RESOURCE LIBRARY | INVESTOR KITS
Biotech Startup Checklist: Investor Readiness
Everything a biotech startup needs to have in place before approaching institutional investors — from science and IP to governance, financials, and investor materials
Updated Q4 2025 | BioPharmaWire Editors | For pre-seed through Series B biotech companies
Investor readiness in biotech is not a single moment — it is a progressive state that evolves from pre-seed through Series B and beyond. The checklist below maps the essentials across six domains: science and IP, clinical strategy and regulatory readiness, team and governance, corporate structure and financials, commercial landscape, and investor-facing materials. Each item is rated by priority (Essential, Important, or Nice to have) and the stage by which it should typically be in place.
No company will have everything on this list before approaching investors at early stages — and experienced investors don’t expect it. What they do expect is that founders understand what they have, what they don’t, and have a credible plan for the gaps. The most fundable early-stage biotechs are not the ones with the most complete checklist — they are the ones where the science is compelling, the team is credible, and the founders understand their own gaps without being defensive about them.
Priority key: Essential Important Nice to have Stage: Pre-Seed Seed Series A Series B+
| Item | What investors look for / why it matters | Priority | By stage |
1. SCIENCE, PLATFORM & INTELLECTUAL PROPERTY | ||||
☐ | Lead compound identified | A specific molecular entity or biological agent with documented activity in a relevant in vitro or in vivo model. Investors need something to assess — a platform without a lead is a technology, not a drug development company. | Essential | Pre-Seed |
☐ | Mechanism of action defined | Clear hypothesis for how the compound produces its biological effect. MOA doesn’t need to be fully proven but must be scientifically credible and differentiated from existing approaches. | Essential | Pre-Seed |
☐ | Proof-of-concept nonclinical data | In vivo efficacy data in a disease-relevant animal model. Single in vitro results are insufficient. Investors want to see that the compound does something in a living system. | Essential | Seed |
☐ | Composition of matter patent filed | Patent protection on the lead compound. Composition of matter is the gold-standard — it protects the molecule itself, not just its use. Without it, freedom to operate and defensibility of the asset are severely weakened. | Essential | Seed |
☐ | Freedom-to-operate (FTO) analysis | Legal analysis confirming the company can develop and commercialise the compound without infringing third-party patents. FTO gaps are a major diligence red flag for institutional investors and acquirers. | Essential | Seed |
☐ | Patent estate mapped | All relevant patents (granted, pending, licensed-in) documented with expiry dates, jurisdictions, and ownership. Investors expect a clear IP summary in the data room. | Important | Series A |
☐ | Manufacturing route established (drug substance) | A viable synthesis or production route for the drug substance at laboratory scale. For biologics: cell line developed and characterised. Investors need confidence the compound can be made in useful quantities. | Important | Seed |
☐ | Formulation development initiated | Early formulation work demonstrating the compound can be delivered to the target tissue. For oral drugs: preliminary solubility, stability, and PK data. For injectables: vehicle identified. | Important | Series A |
2. CLINICAL STRATEGY & REGULATORY READINESS | ||||
☐ | Target indication selected | A specific disease or patient population. ‘Cancer’ is not an indication. ‘Relapsed/refractory IDH1-mutant AML after at least one prior line of therapy’ is an indication. Specificity signals strategic clarity. | Essential | Pre-Seed |
☐ | Unmet medical need documented | Evidence that current standard of care is inadequate for the target population: survival data, response rate benchmarks, quality-of-life data. This is the market narrative and the regulatory rationale simultaneously. | Essential | Seed |
☐ | Regulatory pathway identified | Decision on NDA vs BLA, likely FDA division, applicable expedited programs (Fast Track, BTD, ODD). Has the team spoken with FDA? Even a pre-IND meeting summary demonstrates regulatory sophistication. | Essential | Seed |
☐ | IND strategy defined | Timeline and plan for IND filing. For investors at Series A and beyond, a clear IND filing date is a key milestone. Vague ‘we plan to file an IND’ language without a timeline is a diligence weakness. | Essential | Series A |
☐ | Clinical trial design outlined | Phase 1 design including: starting dose rationale, dose escalation scheme, DLT definitions, primary endpoint (safety/tolerability), secondary endpoints (PK, preliminary efficacy). Investors assess whether the trial is designed to generate fundable data. | Essential | Series A |
☐ | Key opinion leader (KOL) relationships | Relationships with 3-5 leading clinicians in the target indication who have reviewed the data and are willing to be identified as advisors or investigators. KOL endorsement is a strong signal of clinical credibility. | Important | Seed |
☐ | Biomarker and patient selection strategy | If the compound has a predictive biomarker, has a patient selection strategy been defined? Precision medicine programs without a biomarker plan are increasingly viewed as underpowered by sophisticated investors. | Important | Series A |
☐ | Orphan Drug Designation sought (if eligible) | If the indication affects fewer than 200,000 US patients, ODD should be pursued. Investors value ODD as a signal of regulatory engagement and a direct financial benefit (fee waiver, 7-year exclusivity). | Important | Seed |
☐ | IND filed | A filed and active IND is the single most important de-risking milestone before a Series A for most programs. It demonstrates regulatory engagement, IB quality, CMC readiness, and nonclinical package completeness. | Essential | Series A |
☐ | Phase 1 site identified or contracted | Named clinical site(s) with a named principal investigator. Site selection quality (experience with the indication, patient volume, regulatory infrastructure) is assessed by institutional investors. | Important | Series A |
3. TEAM, GOVERNANCE & ADVISORY BOARD | ||||
☐ | CEO with biotech operating experience | Investors fund teams as much as science. A CEO who has previously led a biotech company through IND filing, fundraising, and/or exit is significantly more fundable than a founder-scientist in the CEO role without operational experience. | Essential | Seed |
☐ | CMO or clinical lead identified | A named Chief Medical Officer or VP Clinical Development with relevant therapeutic area experience and ideally prior IND/NDA experience. Can be part-time at early stage but must be identified. | Essential | Series A |
☐ | CSO or scientific founder | A named Chief Scientific Officer with deep expertise in the compound’s mechanism and disease area. Ideally the person who generated the original proof-of-concept data. | Essential | Pre-Seed |
☐ | CFO or financial lead | A named financial lead with biotech fundraising and financial reporting experience. Can be fractional at early stage. Investors need confidence in financial controls and reporting. | Important | Series A |
☐ | Scientific Advisory Board (SAB) constituted | 3-7 advisors with relevant expertise: disease biology, clinical development, regulatory affairs, commercial. Named advisors with documented advisory agreements. Investors check whether SAB members are genuine advocates or nominal names. | Important | Seed |
☐ | Board of Directors established | Formal board with investor representation, independent director(s), and defined governance documents (board charter, committee structure). VC-backed companies are expected to have investor board seats formalised at first institutional close. | Essential | Series A |
☐ | No single key person dependency | The company’s ability to execute must not depend entirely on one person. Key person risk — particularly a single founder-scientist who holds all the scientific knowledge — is a major diligence concern for institutional investors. | Important | Seed |
☐ | Employment and IP assignment agreements | All founders, employees, and consultants must have signed IP assignment agreements confirming that work-product IP belongs to the company. Missing IP assignments are a leading cause of deal failure in due diligence. | Essential | Pre-Seed |
4. CORPORATE STRUCTURE & FINANCIAL READINESS | ||||
☐ | Company incorporated in appropriate jurisdiction | Most VC-backed biotechs incorporate as a Delaware C-corp (US) or equivalent holding structure. Tax and governance implications of jurisdiction should be reviewed with legal counsel before first institutional close. | Essential | Pre-Seed |
☐ | Cap table clean and documented | A fully diluted cap table showing all shareholders, option holders, warrant holders, and convertible note holders. No undocumented equity commitments. Messy cap tables delay or kill financings. | Essential | Seed |
☐ | University license agreement executed | If the technology originated at a university or research institution, the license agreement must be fully executed with clear field-of-use, sublicense rights, milestone and royalty terms, and diligence obligations. Investors scrutinise license terms closely. | Essential | Seed |
☐ | Financial model with 24-month runway plan | A financial model projecting cash burn, milestone spend, and runway under base case and downside assumptions. Investors expect to see that the team understands how much capital is needed and what it will fund. | Essential | Series A |
☐ | Audited or reviewed financials | Reviewed (Series A) or audited (Series B+) financial statements from a recognised accounting firm with biotech experience. Most institutional investors require this before closing. | Important | Series A |
☐ | Data room populated | A structured virtual data room (VDR) containing all key diligence documents: science package, IP, corporate documents, financial model, regulatory filings, team CVs, KOL references. Having a populated VDR signals organisational readiness. | Essential | Series A |
☐ | 409A valuation current | A current 409A independent valuation for US companies. Required for option pricing; options issued without a current 409A create tax liability for employees and legal risk for the company. | Important | Seed |
5. COMMERCIAL LANDSCAPE & MARKET INTELLIGENCE | ||||
☐ | Competitive landscape mapped | A structured analysis of all approved and late-stage investigational treatments in the target indication, with mechanism, efficacy, safety, and commercial data. Investors will do this independently — a company that has done it well inspires confidence. | Essential | Seed |
☐ | Differentiation clearly articulated | A crisp one-paragraph answer to ‘Why is your drug better than what exists or what is coming?’ Differentiation must be based on data, not assertion. ‘Better efficacy’ without evidence is not a differentiation argument. | Essential | Seed |
☐ | Addressable market sized credibly | A bottom-up patient population analysis: diagnosed patients, eligible patients (meeting trial criteria), treatable patients (assuming uptake curve). Top-down market size figures from analyst reports are not credible to experienced investors. | Important | Seed |
☐ | Peak sales estimate with assumptions documented | A peak sales model with explicit assumptions on patient population, penetration rate, price, and timeline to peak. The model will be wrong — investors assess the quality of the assumptions, not the precision of the number. | Important | Series A |
☐ | Pricing and reimbursement landscape assessed | Understanding of how comparable drugs are priced and reimbursed in the target indication. For rare disease programs, this includes awareness of outcome-based contracting trends and ICER reviews. | Important | Series A |
☐ | Partnering and exit landscape understood | A view on which acquirers or licensees are active in the therapeutic area, recent deal comparables, and the company’s likely exit pathway. Not expected at pre-seed, but investors at Series A want to understand the end-game. | Important | Series A |
6. INVESTOR-FACING MATERIALS | ||||
☐ | Executive summary (2 pages) | A two-page document covering: the problem, the solution, the science, the team, the ask, and the use of proceeds. Must be compelling to a reader who knows nothing about the company. The first document most investors read. | Essential | Seed |
☐ | Investor pitch deck (12-15 slides) | A structured investor presentation covering: disease/unmet need, MOA, nonclinical data, clinical plan, competitive differentiation, team, financial ask and use of proceeds, milestones. See BioPharmaWire’s Biotech Pitch Deck Template for the recommended structure. | Essential | Seed |
☐ | Scientific due diligence package | A separate, more detailed scientific document for investor scientific advisors and in-house scientists: full mechanism of action documentation, in vitro and in vivo data tables, nonclinical study summaries, IB if available. | Essential | Series A |
☐ | Pipeline slide | A standard biopharma pipeline chart showing all programs, indication, modality, and clinical stage (preclinical, IND-enabling, Phase 1 etc.). Even a one-program company benefits from a pipeline slide that maps the development trajectory. | Important | Seed |
☐ | Data room with organised folders | Virtual data room with standardised folder structure: Corporate, IP, Science, Clinical & Regulatory, Team, Financials. Folder structure signals professionalism. Investors form impressions of a company from data room organisation. | Essential | Series A |
☐ | Reference list prepared | A list of 5-10 references who can speak to the company: KOLs who have reviewed the science, former colleagues of key team members, angels who invested in the prior round. Investors will ask for references — be ready. | Important | Series A |
What Investors Actually Look For: The Unwritten Standards
The Science Must Be Defensible, Not Just Exciting
Early-stage biotech investors have seen thousands of pitch decks with exciting preclinical data. What separates fundable science from the rest is not the magnitude of the effect — it is the quality of the experimental design, the relevance of the animal model, and the intellectual honesty with which the team presents limitations. A clean, well-controlled experiment with a modest but reproducible effect is more fundable than a dramatic result from a poorly designed study. Investors who do proper scientific due diligence will find the weaknesses regardless — founders who identify them proactively are trusted more.
The Team Must Have Done This Before
The phrase ‘we’re looking for an experienced CEO’ is a warning sign when it appears in a pre-seed pitch deck. Institutional investors at Series A and beyond expect the management team to include people who have previously executed at least one of the key milestones ahead: filing an IND, running a Phase 1 trial, raising a Series B, or negotiating a pharma partnership. Academic founders without operating experience are valuable as scientific advisors — less so as CEOs of companies approaching institutional capital.
The IP Must Be Owned, Not Just Licensed
Investors distinguish between companies that own their core IP and companies that license it from universities or other third parties. Licensed IP is not disqualifying, but it introduces structural risk: the license can be terminated for breach of diligence obligations, the licensor may grant competing licenses, and royalty stacks can make a product commercially unviable before it reaches the market. Companies licensing IP from universities should have their license agreements reviewed by experienced biotech IP counsel before approaching institutional investors. Key terms to have resolved: exclusivity, sublicense rights (particularly to acquirers), change of control provisions, and milestone structure.
The Path to Value Creation Must Be Clear
Biotech investors make money from exits — acquisitions and IPOs. A company that cannot articulate a credible exit pathway within a 7-10 year investment horizon is difficult to fund from a venture capital perspective. Exit pathway articulation does not require a specific buyer or price — it requires a clear answer to: who would want to own this asset at Phase 2 completion, and what would they pay for it? Comparables from recent deals in the therapeutic area are the currency of this conversation.
The Ask Must Match the Plan
The funding ask must be sized to reach a meaningful value-inflection milestone — typically Phase 1 completion and/or a Phase 2 interim readout. Investors are highly attuned to underfunded asks that cannot reach the next milestone without a bridge, and to over-ambitious asks that suggest a founder does not understand burn rates. The right ask is the amount needed to reach the next value-creating milestone with 6 months of runway cushion beyond it.
Common Investor Readiness Gaps by Stage
Pre-Seed / Angel
Red flag: IP not yet filed. Angel investors can accept a pending patent application, but should not invest if no IP filing is planned. At minimum, a provisional patent application should be in process.
Red flag: No incorporation. Investors cannot write a check to an unincorporated entity. Incorporation in a fundable jurisdiction (Delaware C-corp in the US, or equivalent) must happen before any external investment.
Investor lens: At pre-seed, the most important thing is the science and the founding team. Investors at this stage are betting on people and a scientific hypothesis. Everything else can be built.
Seed
Red flag: No KOL validation. Seed investors in biotech almost always check whether respected clinicians in the target indication have reviewed the data and are supportive. A program with no KOL exposure is a material gap.
Red flag: University license not executed. Seed-stage biotechs that have not yet formalised their license from the originating university are not investor-ready. Investors will not fund a company where the core IP ownership is unresolved.
Investor lens: Seed investors are primarily assessing: is the science real, is the team credible, and is the IP defensible? Get these three right and the rest can be built during the seed round.
Series A
Red flag: No IND filed or imminent. A Series A without an active IND or a credible near-term IND filing date is difficult to close with institutional investors. The IND is the proof that the nonclinical package, IB, and CMC are complete enough for FDA to authorise human studies.
Red flag: Cap table not clean. Series A investors conduct formal legal diligence. Undocumented equity grants, missing IP assignments, or unresolved founder equity disputes will kill or delay a Series A close.
Red flag: Financial model not credible. A model that assumes flat burn, ignores clinical CRO costs, or projects revenue before Phase 2 completion will be immediately identified as unsophisticated by institutional investors.
Investor lens: At Series A, the ask is typically $20-60M to fund Phase 1 and early Phase 2. The pitch centres on: we have de-risked the science to IND, here is our Phase 1 design, here is what the data will look like if we’re right, and here is who will want to buy us when we get there.
This checklist is an editorial product of BioPharmaWire intended as a general investor readiness guide for early-stage biotech companies. It reflects common expectations among institutional life sciences investors as of Q4 2025 and does not constitute financial, legal, or investment advice. Individual investor expectations vary — founders should engage experienced biotech counsel and financial advisors before approaching institutional capital.